Securing branding for pharmaceuticals in Australia is a two-tiered process in a highly regulated market. New trademarks must go through both the IP Australia registration process and the Therapeutic Goods Administration (TGA) approval process for regulatory clearance as part of the broader category of ‘therapeutic goods’. In addition, a critical distinction exists in the market between prescription medicines and over-the-counter (OTC) medicines; each has its own distinct subset of issues for establishing and protecting brands.

Selection, clearance and registration

Like other mature markets, Australia suffers from a crowded register in the pharmaceutical space, with many registrations in Class 5. The legislative regime facilitated by IP Australia still provides for full examination for both inherent and relative registrability, thereby preventing the registration of trademarks which:

  • conflict with prior similar applications or registered trademarks;
  • are likely to deceive or cause confusion with unregistered marks; or
  • are incapable of distinguishing the goods or services claimed in the specification.

For pharmaceutical companies establishing new brands and products, obtaining clearance for a mark that is not conflicting, deceptive or confusing can be difficult. Comprehensive searches and clearances are needed before a product name is settled on for the Australian market.

IP Australia may also reject trademarks or parts of trademarks which are registered in relation to pharmaceuticals or veterinary substances:

  • that contain an international non-proprietary name (INN) stem or a notified INN stem in a meaningful way, or are the same as or may connote a notified INN; and
  • whose use in respect of the goods covered by the specification is not restricted to the particular substance indicated by the INN.

Brand owners should plan their product expansion in Australia carefully. Trademarks for prescription medicines, which cannot be advertised to the general public, can be easier to register because the courts consider the risk of confusion among pharmacists to be lower than that among the purchasing public. However, many pharmaceutical brands have evolved from their prescription-only origin into OTC products, and further still into lifestyle goods and services. A forward-thinking strategy for clearance and selection is often needed. A mark which is distinctive and not confusing in the prescription space may be vulnerable once the product enters the OTC market, where the risk of consumer confusion is more acute.

For example, GlaxoSmithKline’s ZOVIRAX trademark was initially used on an antiviral prescription medication. The brand was later used on an OTC antiviral cream and has recently expanded to be used on a cold sore awareness website and a patch product. ZOVIRAX is a strong and distinctive trademark which makes those expansions achievable.

Potential marks which have not been vetted with future business expansion in mind can face difficulties from established brands as they grow into new and related classes of goods and/or services.

As pharmaceutical companies seek ways to manage longevity in a competitive market, there has been rapid growth in the filing of trademarks – for example, overall packaging design or get-up, container shapes and colour combinations. There have not yet been any applications for sounds or smells. There are 60 registered shape marks in Class 5 and a further 17 pending.

Regulatory approvals – proposed new packaging requirements

The TGA regulates all medicines, even those with homeopathic ingredients. At present, any new medicine name must be presented for approval before a medicine can be listed for sale. In practice, the TGA looks at a product’s name only to ensure consumer safety. However, the TGA has released a draft order which seeks to further regulate pharmaceutical packaging in Australia, particularly in relation to minimum font sizes, the prominence of active ingredients, the designated space for dispensing labels and the use of the medicine information panel.

If the draft order is adopted, many brand owners may face greater difficulties in differentiating their products from those of competitors, particularly generic medicines. This may introduce a new hurdle for the selection and clearance of packaging designs and product get-up.

Key proposals in the new draft order include the following:

  • Standardisation of packaging – the draft order includes requirements for mandatory font sizes, colouring and the prominence of active ingredients, although different rules will apply where a product has four or more active ingredients.
  • Medicine information panel – a medicine information panel will be introduced to standardise information formatting for non-prescription medicines.
  • Dispensing labels – the TGA has included in the draft order its recommendation for designated clear spaces on packaging for pharmacists to attach dispensing labels to prescription medicines.
  • Blister strip labelling – the draft order has adopted requirements that the name, active ingredient and strength appear at least once across each every two dosage units, even where the sections cannot be detached from the main package.

The consultation period concluded on October 7 2014 and results were presented to the government in late 2014. A transition period of three to four years for compliance with the new standards is contemplated; however, the TGA notes that this period will be determined following the consultation process.

Parallel imports

Any pharmaceutical which is registered with the TGA can theoretically be parallel imported. The products most at risk are those which fall within the fast-moving consumer goods space, such as toothpastes, medical devices, bandages and so forth. Australia follows the known principle of worldwide exhaustion.

Australian trademark law focuses on the concept of a trademark being a badge of origin rather than a badge of control and provides a defence for selling genuine goods.

However, recent case law in Australia restated the limits of this defence. Importers of grey-market goods will be liable where goods are imported if the brand owner has consented for a trademark to be applied only in expressly specific territories. Pharmaceutical companies concerned about the import of grey-market goods should ensure that consents and licences expressly specify relevant territories to prevent parallel imports into Australia. This can be a particular challenge when products are manufactured in one location for supply to several countries.

Anti-counterfeiting and enforcement

Given the tightly regulated market for both the sale of pharmaceuticals and the operation of pharmacies, the sale of counterfeit pharmaceuticals is not a serious problem in Australia.

Customs seizures

The customs recordal procedure enables the Australian Customs and Border Protection Service to seize products which are suspected to be counterfeit. The customs notice enforcement system applies to commercial quantities of goods. Overall, the process is relatively inexpensive and a useful enforcement tool.

The process is as follows:

  • A customs notice application must be filed with Customs detailing the registered trademark rights on which the notice is based. The general customs recommendation is to list all registered marks to ensure that a wide net for counterfeit goods can be cast.
  • Customs will place a watch over only commercial quantities of goods. This may not catch purchases from overseas-based websites, which often send orders directly to the end consumer from outside Australia (ie, goods are not imported into Australia in commercial quantities).
  • If Customs seizes a suspect shipment and the importer refuses to forfeit the goods to the objector, the objector has 10 days to commence legal action against the importer (during which time the importer can voluntarily forfeit goods to the government). This 10-day period may be extended by a further 10 days only.

Goods are automatically forfeited to the government unless the importer files a claim for release with Customs.

Advertising

Australia is a highly regulated advertising market with strong consumer protection, particularly for pharmaceutical products. There are two principal sources of advertising regulation:

  • the Consumer Law, which features, among other things, a blanket general prohibition on “misleading or deceptive conduct”; and
  • industry codes of practice or conduct that may have the force of law or are self-regulated by industry groups.

The advertising of pharmaceutical products is highly regulated through a co-regulatory model consisting of the TGA and industry bodies. The key sources of regulation are the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990 and the Therapeutic Goods Advertising Code. Advertisements must also comply with the applicable industry code of practice.

The TGA broadly classifies pharmaceuticals into three categories of regulation:

  • A ‘prescription medicine’ is generally a medicine that requires prescription by a registered healthcare practitioner. Approval of a generic prescription medicine follows a similar process to new prescription medicines.
  • An ‘OTC medicine’ is generally a medicine that can be purchased without a prescription, but from a pharmacy or in some cases from the supermarket.
  • A ‘complementary medicine’ includes herbal or ‘traditional’ medicines and vitamins and homeopathic products.
  • Regulation also exists for medical devices, biological products and miscellaneous “other therapeutic goods”.
  • Pharmaceutical branding and advertisements may typically require compliance with:
  • the Medicines Australia Code of Conduct, for advertisements of branded prescription products;
  • the Generic Medicines Industry of Australia Code of Practice, for advertisements of generic prescription products;
  • the Australian Self-medication Industry Code of Practice, for advertisements of non-prescription (OTC) products; and
  • the Complementary Healthcare Council of Australia Marketing Code of Practice, for advertisements of complementary medicines.

Prescription medicines cannot be advertised to the general public in Australia, although the Therapeutic Goods Act and the Medicines Australia Code of Conduct allows brands to advertise to healthcare professionals. Prior approval is required for certain types of ad and generic information advertised directly to consumers in broadcast media, print media, outdoor advertising or cinema advertising.

In general, compliance with consumer legislation, therapeutic goods regulation and industry codes requires that advertisements not:

  • be unrealistic about their claims of effectiveness;
  • cause consumers to self-diagnose or treat potentially serious conditions inappropriately;
  • exploit consumers’ relative lack of understanding;
  • use distressing or fear-inducing language;
  • take advantage of a consumer’s lack of understanding;
  • use language designed to bring about fear or distress;
  • encourage customers to use medications to excess or in inappropriate doses;
  • claim that the medicine is effective for every case or all cases; and
  • underemphasise or disregard side effects.

Advertising directed towards minors or certain serious conditions is more strictly regulated.

The Australian regulatory system has a complaints procedure, which differs depending on the particular product that is involved and how it was advertised.

There is significant crossover with Australia’s consumer protection laws. The general prohibition against misleading and deceptive conduct requires constant diligence for many brands operating in the jurisdiction. For example, the Australian Competition and Consumer Commission, which enforces Australian consumer regulations, has indicated that it is taking a particular regulatory focus on ‘credence claims’.

Of particular concern to pharmaceutical companies is the increase in the use of the Internet to advertise and sell pharmaceuticals. For example, US websites may not comply with Australian regulations. The use of social media is very common for OTC products. Pharmaceutical companies must regulate their social media accounts in case users post information such as product claims or recommendations which contravene any of the industry codes. In 2011 an action was brought against Allergy Pathway, which was found to be liable for misleading and deceptive third-party testimonials written by clients and posted on its Facebook wall. In that case, the Federal Court held Allergy Pathway to be the ‘publisher’ (in breach of an earlier proffered undertaking), because it knew of the specific posts and did not remove them.

Food standards codes for fortified products

Fortified food branding and trademarks are also subject to regulation. A trademark can amount to a nutritional or health claim if it contains a word which describes an ingredient or effect, such as ‘calci’ where there is no calcium or less than a prescribed amount in the product.

The Food Standards Code, regulated by Food Standards Australia New Zealand, includes detailed provisions about how nutrition and health claims can be made in food. For example, where fortified food makes nutrition claims, the Food Standard Code requires detailed minimum nutrient content requirement be met before the nutrition claim can be made.

The Food Standards Code also sets out pre-approved food health relationships, and although there is provision for limited self-substantiation, generally health claims can be made only if they are in relation to those pre-approved guidelines.

Generic substitution

Generic medicines are widely used in Australia. Approximately 40% of the prescriptions filled on the government’s subsidised Pharmaceutical Benefits Scheme (PBS) are for generic medicines.

For registration with the TGA, a generic medicine must, in comparison to the originator product:

  • have the same quantitative composition of therapeutically active substances, being substances of similar quality to those in the originator product;
  • have the same pharmaceutical form;
  • be bioequivalent; and
  • have the same safety and efficacy properties.

The promotion by the PBS of generics causes numerous issues for brand owners, as generic companies often adopt trademarks and get-up which are similar to those of originator pharmaceuticals. The changes to the packaging requirements discussed above appear to promote this practice to make generic medicines more easily accepted.

Online issues

Generally, online pharmacies may sell only OTC products. Prescription medications are sold only through traditional pharmacies which are regulated at both the state and federal level.

As outlined above, prescription medications cannot be advertised. While there is a requirement that advertisements for drugs that may be advertised be approved in relation to specified media (including radio and television), the position in relation to online advertising is unclear. The main issues relate to spill-over from other countries and social media.

All advertisements, including those on the Internet, must comply with the more general provisions of the Therapeutic Goods Act, the Therapeutic Goods Advertising Code and the relevant consumer laws.

Norton Rose Fulbright

Level 18, Grosvenor Place

225 George Street

Sydney NSW 2000

Australia

Tel +61 2 9330 8000

Fax +61 2 9330 8111

Web www.nortonrosefulbright.com

Frances Drummond

Partner

frances.drummond@nortonrosefulbright.com

 

Frances Drummond has more than 25 years’ experience of practising IP law in Europe, Asia and Australia. She manages trademark portfolios for leading global and local brands and is particularly interested in the pharmaceutical industry.

Ms Drummond regularly presents seminars locally and abroad on issues associated with trademark protection. She authors articles and publications on trademark law.

Ms Drummond is admitted to practise in Australia, Hong Kong and the United Kingdom, and is a UK registered trademark attorney. She is a member of industry bodies including the UK Institute of Trademark Attorneys, the Pharmaceutical Trademarks Group and the International Trademark Association.

Luke Hawthorne

Lawyer

luke.hawthorne@nortonrosefulbright.com

 

Luke Hawthorne is an IP lawyer based in Sydney. He specialises in contentious IP disputes concerning copyright, trademarks, designs and patents. His industry experience includes work in the technology, pharmaceuticals, energy and media and entertainment industries.

Mr Hawthorne has assisted in a diverse range of advisory and transactional work for the creation, ownership, registration, transfer, licensing and strategic protection of brands and intellectual property.

His ability to meet “the challenges of working on a complex, protracted case” has been recognised by Australian Lawyers Weekly naming him a finalist for the ‘Young Gun’ of 2014 in the Australian Law Awards.

This article first appeared in World Trademark Review. For further information please visit www.worldtrademarkreview.com.